The clinical trials below are available in the specialty you selected. Choose a different specialty.
A Controlled Trial of Transcranial Direct Current Stimulation as a Treatment for Unipolar and Bipolar Depression
Are You Depressed?
➢ If you are age 18 or over and are suffering from symptoms of depression you may qualify to participate in a 9-week research study at Duke University.
➢ Benefits may include a medical evaluation and monitoring for your depression. (REF# Pro00035794)
Neurocognitive Research Study
The purpose of this study is to evaluate the psychometric properties and utility of new, computerized, neurocognitive measures originally designed for non-human primates, in healthy control humans, humans with depression, and humans with depression undergoing electroconvulsive therapy (ECT). The benefits of the study outweigh the risk as there is the possibility of developing better computerized neurocognitive measures, and the risks are limited to no more than minimal test related fatigue and psychological stress. (REF# Pro00039288)
STEADi is a clinical research study being done to find out if an investigational drug is safe and if it works for adolescents who have major depressive disorder (MDD). The investigational drug being used in this study is approved and available for use in adults, but has not been approved for use in children or adolescents. (REF# 00047176)
Evaluation of Moclobemide, a reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
The purpose of this study is to assess the efficacy of moclobemide, a selective, reversible MAO-A inhibitor, in facilitating smoking cessation in treatment-seeking female smokers..
This study consists of a physical screening session (scheduled between 8:00 am and 2:30 pm Monday through Friday) and seven study visits over a 12-week period. You may also be asked to come in for a follow-up visit six months after your quit day. (REF# 00044174)
A Prospective, Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H-Coil deep Transcranial Magnetic Stimulation (dTMS) in Conjunction with Mood Stabilizers in Subjects with Bipolar Depression
A research study is being conducted at Duke University Medical Center to evaluate whether dTMS is safe and effective in treating bipolar depression in individuals who are currently taking mood stabilizers and previously have been treated unsuccessfully with antidepressant medications. (REF# Pro00034547)
Researchers are seeking healthy volunteers for participation in a study aimed at reducing the risk of heart disease and type 2 diabetes in at-risk individuals. (REF# 16540)
Nicotine, Non-Smokers with and without ADHD, and Genetics Study (NNSG)
The main purpose of the NNSG study is to evaluate the effects of nicotine exposure in a group of nonsmoking young adults with and without ADHD. (REF# Pro00037792)
ADHD Adolescent Medication Study
We are looking for adolescents 13-17 years old who may have ADHD to participate in a nationwide research study testing two FDA approved drugs for ADHD. ADHD evaluation and study drug will be provided at no cost to those who qualify. (REF# 00038164)
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adults.
The purpose of this study is to determine if a new formulation of ramelteon (TAK-375SL) is effective in decreasing the symptoms of depression associated with bipolar I disorder so the study evaluates using an additional drug to your current medication to control depression in bipolar individuals. (REF# Pro00034212)
A Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 Tablet for Sublingual Administration in the Treatment of Acute Depressive Episodes
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg, 0.4 mg, and 0.8 mg in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate (REF# Pro00034200)